Sarepta Gene Therapy Halt - Search News

Order byBest matchMost fresh

News

FDA, Sarepta

· 1h · on MSN

Sarepta extends losses premarket after refusing FDA’s halt request

Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second session after plunging 36% on Friday.

Continue reading

· 2d · on MSN

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

pharmaphorum · 2h

Sarepta resists as FDA seeks pause on Elevidys use

8hon MSN

FDA Suspends Muscular Dystrophy Drug After 3 Patient Deaths

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...

2d

Sarepta Therapeutics crisis is huge blow to Duchenne families, company

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results